Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples